<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
(Amendment No. )*
Schein Pharmaceutical, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $.01 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
806416103
- --------------------------------------------------------------------------------
(CUSIP Number)
*The remainder of this cover page shall be filled out for a reporting
person's initial filing on this form with respect to the subject class of
securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be
deemed to be "filed" for the purpose of Section 18 of the Securities
Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that
section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
Page 1 of 9 pages
<PAGE>
CUSIP No. 806416103 13G Page 2 of 9 Pages
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Judith Shafran and Irving Shafran as trustees U/A dated October 26, 1994,
Pamela M. Schein as grantor
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
(b) X
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
5 SOLE VOTING POWER
-0-
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 6,636,210
WITH
8 SHARED DISPOSITIVE POWER
-0-
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
6,636,210
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
20.61%
12 TYPE OF REPORTING PERSON*
IN
*SEE INSTRUCTION BEFORE FILLING OUT!
Page 2 of 9 pages
<PAGE>
CUSIP No. 806416103 13G Page 3 of 9 Pages
1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON
Robert D. Villency and Irving Shafran as trustees of The Pamela M.
Schein Issue Trust, dated September 29, 1994
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a)
(b) X
3 SEC USE ONLY
4 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
5 SOLE VOTING POWER
-0-
NUMBER OF 6 SHARED VOTING POWER
SHARES
BENEFICIALLY -0-
OWNED BY
EACH 7 SOLE DISPOSITIVE POWER
REPORTING
PERSON 508,200
WITH
8 SHARED DISPOSITIVE POWER
-0-
9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
508,200
10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
1.58%
12 TYPE OF REPORTING PERSON*
IN
*SEE INSTRUCTION BEFORE FILLING OUT!
Page 3 of 9 pages
<PAGE>
Item 1(a). Name of Issuer:
Schein Pharmaceutical, Inc. (the "Issuer")
Item 1(b). Address of Issuer's Principal Executive Offices:
100 Campus Drive
Florham Park, NJ 07932
Items 2(a) Name of Person Filing; Address of Principal
and (b). Business Office:
This Statement is being filed on behalf of Irving Shafran,
Judith Shafran and Robert D. Villency. Pursuant to the
terms of the trusts, Irving Shafran and Judith Shafran, on
one hand, and Irving Shafran and Robert D. Villency, on
the other hand, are deemed beneficial owners, due to their
investment powers, of the shares of Common Stock (as
defined below) of the Issuer held by the Trusts and
reported herein.
Each Trust's address is c/o Willkie Farr & Gallagher, 787
Seventh Avenue, New York, NY 10019.
Item 2(c). Citizenship:
Mr. Shafran, Mrs. Shafran and Mr. Villency are United
States citizens.
Item 2(d). Title of Class of Securities:
Common Stock, par value $.01 per share (the "Common
Stock")
Item 2(e). CUSIP Number:
806416103
Item 3. Not Applicable
Item 4. Ownership:
Item 4(a) Amount Beneficially Owned:
Each of the Reporting Persons may be deemed the beneficial
owner of the following number of shares of Common Stock:
i) Mr. Shafran may be deemed the beneficial owner of
7,144,410 shares of Common Stock;
Page 4 of 9 pages
<PAGE>
ii) Mrs. Shafran may be deemed the beneficial owner of
6,636,210 shares of Common Stock; and
iii) Mr. Villency may be deemed the beneficial owner of
508,200 shares of Common Stock.
Item 4(b) Percent of Class:
i) The number of shares of Common Stock of which Mr.
Shafran may be deemed the beneficial owner constitutes
approximately 22.19% of the total number of such shares
outstanding.
ii) The number of shares of Common Stock of which Mrs.
Shafran may be deemed the beneficial owner constitutes
approximately 20.61% of the total number of such shares
outstanding.
iii) The number of shares of Common Stock of which Mr.
Villency may be deemed the beneficial owner constitutes
approximately 1.58% of the total number of such shares
outstanding.
Item 4(c) Number of shares of Common Stock to which the
Reporting Person has:
Mr. Shafran
(i) Sole power to vote or to direct the vote: -0-
(ii) Shared power to vote or to direct the vote: -0-
(iii) Sole power to dispose or to direct the disposition
of: 7,144,410
(iv) Shared power to dispose or to direct the disposition
of: -0-
Mrs. Shafran
(i) Sole power to vote or to direct the vote: -0-
(ii) Shared power to vote or to direct the vote: -0-
(iii) Sole power to dispose or to direct the disposition
of: 6,636,210
(iv) Shared power to dispose or to direct the disposition
of: -0-
Mr. Villency
(i) Sole power to vote or to direct the vote: -0-
(ii) Shared power to vote or to direct the vote: -0-
(iii) Sole power to dispose or to direct the disposition
of: 508,200
Page 5 of 9 pages
<PAGE>
(iv) Shared power to dispose or to direct the disposition
of: -0-
Item 5. Ownership of Five Percent or Less of a Class:
Not Applicable
Item 6. Ownership of More than Five Percent on Behalf of
Another Person:
Not Applicable
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on By the Parent
Holding Company:
Not Applicable
Item 8. Identification and Classification of Members of
the Group:
Not Applicable
Item 9. Notice of Dissolution of Group:
Not Applicable
Item 10. Certification:
Not Applicable
Page 6 of 9 pages
<PAGE>
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
Dated: June 15, 1998
By: /s/ Irving Shafran
----------------------------
Name: Irving Shafran
Title: Trustee
By: /s/ Judith Shafran
----------------------------
Name: Judith Shafran
Title: Trustee
By: /s/ Robert D. Villency
----------------------------
Name: Robert D. Villency
Title: Trustee
Page 7 of 9 pages
<PAGE>
EXHIBIT INDEX
Exhibit No. Description Page
1 Joint Filing Agreement, dated 9
June 15, 1998, among the signatories
to this Schedule 13G.
Page 8 of 9
<PAGE>
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k)(1)
The undersigned hereby agree that the statement on Schedule 13G with
respect to the shares of Schein Pharaceutical, Inc. dated as of June 15, 1998
is, and any amendments thereto (including any amendments on Schedule 13D)
signed by each of the undersigned shall be, filed on behalf of us pursuant to
and in accordance with the provisions of Rule 13d-1(k) under the Securities
Exchange Act of 1934.
Dated: June 15, 1998
By: /s/ Irving Shafran
----------------------------
Name: Irving Shafran
Title: Trustee
By: /s/ Judith Shafran
----------------------------
Name: Judith Shafran
Title: Trustee
By: /s/ Robert D. Villency
----------------------------
Name: Robert D. Villency
Title: Trustee
Page 9 of 9 pages
